{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:06:41Z","timestamp":1744344401873,"version":"3.40.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00120-025-02550-4","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:59:22Z","timestamp":1741604362000},"page":"352-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interessenkonflikte bei wissenschaftlichen Publikationen und m\u00f6gliche Konsequenzen","Conflicts of interest in scientific publications and possible consequences"],"prefix":"10.1007","volume":"64","author":[{"given":"Jonas","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Netsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2550_CR1","unstructured":"Gravas S et\u00a0al (2023) EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Eur Urol"},{"key":"2550_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.clinthera.2021.11.019","volume":"44","author":"RL Morrow","year":"2022","unstructured":"Morrow\u00a0RL, Mintzes\u00a0B, Gray\u00a0G et\u00a0al (2022) Industry Sponsor Influence in Clinical Trial Reporting in Canada: A\u00a0Qualitative Interview Study. Clin Ther 44:374","journal-title":"Clin Ther"},{"key":"2550_CR3","first-page":"2012","volume":"187","author":"LA Hampson","year":"1971","unstructured":"Hampson\u00a0LA, Montie\u00a0JE (1971) Conflict of interest in urology. J\u00a0Urol 187:2012","journal-title":"J Urol"},{"key":"2550_CR4","first-page":"Mr000033","volume":"2","author":"A Lundh","year":"2017","unstructured":"Lundh\u00a0A, Lexchin\u00a0J, Mintzes\u00a0B et\u00a0al (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:Mr33","journal-title":"Cochrane Database Syst Rev"},{"key":"2550_CR5","doi-asserted-by":"publisher","first-page":"f3830","DOI":"10.1136\/bmj.f3830","volume":"346","author":"J Lenzer","year":"2013","unstructured":"Lenzer\u00a0J (2013) Why we can\u2019t trust clinical guidelines. BMJ 346:f3830","journal-title":"BMJ"},{"key":"2550_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12913-018-3043-8","volume":"18","author":"M Sharma","year":"2018","unstructured":"Sharma\u00a0M, Vadhariya\u00a0A, Johnson\u00a0ML et\u00a0al (2018) Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data. BMC Health Serv Res 18:236","journal-title":"BMC Health Serv Res"},{"key":"2550_CR7","doi-asserted-by":"crossref","unstructured":"Gilling P, Barber N, Bidair M (2018) Water: a\u00a0double-blind, randomized, controlled trial of aquablation\u00ae vs transurethral resection of the prostate in benign prostatic hyperplasia. J\u00a0Urol","DOI":"10.1016\/j.juro.2017.12.065"},{"key":"2550_CR8","doi-asserted-by":"crossref","unstructured":"Gilling PJ, Barber N, Bidair M (2019) Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology","DOI":"10.1016\/j.urology.2018.12.002"},{"key":"2550_CR9","doi-asserted-by":"crossref","unstructured":"Gilling P, Barber N, Bidair M (2019) Two-year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther","DOI":"10.1016\/S2666-1683(20)32809-3"},{"key":"2550_CR10","doi-asserted-by":"crossref","unstructured":"Gilling P, Barber N, Bidair M (2020) Three-year outcomes after aquablation therapy compared to TURP: results from a\u00a0blinded randomized trial. Can J Urol","DOI":"10.1016\/S2666-1683(20)32809-3"},{"key":"2550_CR11","doi-asserted-by":"crossref","unstructured":"Gilling PJ, Barber N, Bidair M (2022) Five-year outcomes for Aquablation therapy compared to TURP: results from a\u00a0double-blind, randomized trial in men with LUTS due to BPH. Can J Urol","DOI":"10.1016\/S0302-2838(22)00965-4"},{"key":"2550_CR12","doi-asserted-by":"crossref","unstructured":"Gilfrich C, May M, Fahlenbrach C (2021) Surgical Reintervention Rates after Invasive Treatment for Lower Urinary Tract Symptoms due to Benign Prostatic Syndrome: A\u00a0Comparative Study of More than 43,000 Patients with Long-Term Followup. J\u00a0Urol","DOI":"10.1097\/JU.0000000000001463"},{"key":"2550_CR13","doi-asserted-by":"crossref","unstructured":"Desai M, Bidair M, Bhojani N (2019) Water II (80\u2013150\u202fmL) procedural outcomes. BJU Int","DOI":"10.1111\/bju.14360"},{"key":"2550_CR14","doi-asserted-by":"crossref","unstructured":"Zorn KC, Goldenberg SL, Paterson R (2019) Aquablation among novice users in Canada: a\u00a0Water II subpopulation analysis. Can Urol Assoc\u00a0J","DOI":"10.5489\/cuaj.5501"},{"key":"2550_CR15","doi-asserted-by":"crossref","unstructured":"Desai M, Bidair M, Zorn KC (2019) Aquablation for benign prostatic hyperplasia in large prostates (80\u2013150\u202fmL): 6\u2011month results from the Water II trial. BJU Int","DOI":"10.1016\/S1569-9056(19)31078-4"},{"key":"2550_CR16","doi-asserted-by":"crossref","unstructured":"Zorn KC, Bidair M, Trainer A (2021) Aquablation therapy in large prostates (80\u2013150\u202fcc) for lower urinary tract symptoms due to benign prostatic hyperplasia: Water II 3\u2011year trial results. BJUI Compass","DOI":"10.1002\/bco2.121"},{"key":"2550_CR17","doi-asserted-by":"crossref","unstructured":"Bhojani N, Bidair M, Kramolowsky E (2023) Aquablation Therapy in Large Prostates (80\u2013150\u202fmL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final Water II 5\u2011Year Clinical Trial Results. J\u00a0Urol","DOI":"10.1097\/JU.0000000000003483"},{"key":"2550_CR18","doi-asserted-by":"crossref","unstructured":"Michaelis J, Tr\u00e4ger M, Astheimer S (2024) Aquablation versus HoLEP in patients with benign prostatic hyperplasia: a\u00a0comparative prospective non-randomized study. World J Urol","DOI":"10.1007\/s00345-024-04997-0"},{"key":"2550_CR19","doi-asserted-by":"crossref","unstructured":"Gross AJ, Lipp MJ, Baumbach R (2021) Rectal perforation after aquablation of the prostate: lessons learned the hard way. World J Urol","DOI":"10.1007\/s00345-021-03660-2"},{"key":"2550_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/end.2021.0455","volume":"36","author":"E Kaplan-Marans","year":"2022","unstructured":"Kaplan-Marans\u00a0E, Martinez\u00a0M, Wood\u00a0A et\u00a0al (2022) Aquablation, Prostatic Urethral Lift, and Transurethral Water Vapor Therapy: A\u00a0Comparison of Device-Related Adverse Events in a\u00a0National Registry. J\u00a0Endourol 36:231","journal-title":"J Endourol"},{"key":"2550_CR21","doi-asserted-by":"crossref","unstructured":"McVary KT, Gange SN, Gittelman MC et\u00a0al (1529) Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A\u00a0Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J\u00a0Urol 195:2016","DOI":"10.1016\/j.juro.2015.10.181"},{"key":"2550_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/JU.0000000000001778","volume":"206","author":"KT McVary","year":"2021","unstructured":"McVary\u00a0KT, Gittelman\u00a0MC, Goldberg\u00a0KA et\u00a0al (2021) Final 5\u2011Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a\u00a0Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J\u00a0Urol 206:715","journal-title":"J Urol"},{"key":"2550_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","volume":"111","author":"KT McVary","year":"2018","unstructured":"McVary\u00a0KT, Roehrborn\u00a0CG (2018) Three-Year Outcomes of the Prospective, Randomized Controlled Rez\u016bm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Urology 111:1","journal-title":"Urology"},{"key":"2550_CR24","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, Gange SN, Gittelman MC et\u00a0al (1507) Convective Thermal Therapy: Durable 2\u2011Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. J\u00a0Urol 197:2017","DOI":"10.1016\/j.juro.2016.12.045"},{"key":"2550_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary\u00a0KT, Rogers\u00a0T, Roehrborn\u00a0CG (2019) Rez\u016bm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4\u2011Year Results From Randomized Controlled Study. Urology 126:171","journal-title":"Urology"},{"key":"2550_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11934-020-00985-0","volume":"21","author":"R Dornbier","year":"2020","unstructured":"Dornbier\u00a0R, Pahouja\u00a0G, Branch\u00a0J et\u00a0al (2020) The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update. Curr Urol Rep 21:32","journal-title":"Curr Urol Rep"},{"key":"2550_CR27","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn\u00a0CG, Barkin\u00a0J, Gange\u00a0SN et\u00a0al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24:8802","journal-title":"Can J Urol"},{"key":"2550_CR28","first-page":"7772","volume":"22","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn\u00a0CG, Rukstalis\u00a0DB, Barkin\u00a0J et\u00a0al (2015) Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 22:7772","journal-title":"Can J Urol"},{"key":"2550_CR29","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn\u00a0CG, Gange\u00a0SN, Shore\u00a0ND et\u00a0al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J\u00a0Urol 190:2161","journal-title":"J Urol"},{"key":"2550_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke\u00a0C, Barber\u00a0N, Speakman\u00a0MJ et\u00a0al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2\u2011year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119:767","journal-title":"BJU Int"},{"key":"2550_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.eururo.2015.04.024","volume":"68","author":"J S\u00f8nksen","year":"2015","unstructured":"S\u00f8nksen\u00a0J, Barber\u00a0NJ, Speakman\u00a0MJ et\u00a0al (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68:643","journal-title":"Eur Urol"},{"key":"2550_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","volume":"180","author":"O Reich","year":"2008","unstructured":"Reich\u00a0O, Gratzke\u00a0C, Bachmann\u00a0A et\u00a0al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a\u00a0prospective multicenter evaluation of 10,654 patients. J\u00a0Urol 180:246","journal-title":"J Urol"},{"key":"2550_CR33","doi-asserted-by":"crossref","unstructured":"Peppercorn J, Blood E, Winer E et\u00a0al (2007) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. 109:1239","DOI":"10.1002\/cncr.22528"},{"key":"2550_CR34","doi-asserted-by":"crossref","unstructured":"Tibau A, Bedard PL, Srikanthan A et\u00a0al (2015) Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. 33:100","DOI":"10.1200\/JCO.2014.57.8898"},{"key":"2550_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.eururo.2018.04.023","volume":"74","author":"A Carlisle","year":"2018","unstructured":"Carlisle\u00a0A, Bowers\u00a0A, Wayant\u00a0C et\u00a0al (2018) Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines. Eur Urol 74:348","journal-title":"Eur Urol"},{"key":"2550_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2021.10.025","volume":"159","author":"A Singh","year":"2022","unstructured":"Singh\u00a0A, Faris\u00a0S, Agarwal\u00a0P et\u00a0al (2022) Association between Industry Payments and Published Position on Use of Devices for the Treatment of Lower Urinary Tract Symptoms. Urology 159:87","journal-title":"Urology"},{"key":"2550_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00240-022-01397-0","volume":"51","author":"AL Rodgers","year":"2022","unstructured":"Rodgers\u00a0AL (2022) Conflicts of interest and the risk of bias are inevitable in urolithiasis research. Urolithiasis 51:24","journal-title":"Urolithiasis"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02550-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02550-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02550-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:27:30Z","timestamp":1744280850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02550-4"}},"subtitle":["Eine kritische Analyse am Beispiel der benignen Prostatahyperplasie (BPH)","A critical analysis using the example of benign prostatic hyperplasia (BPH)"],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2550"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02550-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"31 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Herrmann gibt folgenden Interessenkonflikt an: Boston Scientific: Proctor f\u00fcr HoLEP Operationen. C.\u00a0Netsch gibt folgenden Interessenkonflikt an: Richard Wolf: Proctor, Consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}